Nicolas Gordon

704 total citations
15 papers, 375 citations indexed

About

Nicolas Gordon is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Nicolas Gordon has authored 15 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Reproductive Medicine. Recurrent topics in Nicolas Gordon's work include PARP inhibition in cancer therapy (11 papers), Ovarian cancer diagnosis and treatment (6 papers) and BRCA gene mutations in cancer (4 papers). Nicolas Gordon is often cited by papers focused on PARP inhibition in cancer therapy (11 papers), Ovarian cancer diagnosis and treatment (6 papers) and BRCA gene mutations in cancer (4 papers). Nicolas Gordon collaborates with scholars based in United States, Netherlands and Germany. Nicolas Gordon's co-authors include Elise C. Kohn, Minshu Yu, Jung Min Lee, Christina M. Annunziata, Lori M. Minasian, Tristan M. Sissung, William D. Figg, John L. Hays, Bradford J. Wood and James H. Doroshow and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Nicolas Gordon

15 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Gordon United States	7	230	176	97	87	56	15	375
Anne‐Louise Gannon Australia	6	186 0.8×	231 1.3×	62 0.6×	56 0.6×	3 0.1×	13	386
Jon Greenberg Germany	8	115 0.5×	100 0.6×	81 0.8×	23 0.3×	13 0.2×	14	330
Hisanori Matsumoto Japan	11	136 0.6×	234 1.3×	51 0.5×	27 0.3×	2 0.0×	21	443
Pravin Nahar Australia	12	65 0.3×	102 0.6×	135 1.4×	62 0.7×	5 0.1×	13	343
Yuqian Wang China	12	17 0.1×	169 1.0×	121 1.2×	84 1.0×	7 0.1×	29	393
Koji Okuhara Japan	11	37 0.2×	304 1.7×	13 0.1×	72 0.8×	6 0.1×	23	411
Behzad M. Toosi Canada	11	25 0.1×	90 0.5×	27 0.3×	55 0.6×	17 0.3×	27	248
Juhura G. Almazi Australia	9	19 0.1×	175 1.0×	91 0.9×	28 0.3×	4 0.1×	15	360

Countries citing papers authored by Nicolas Gordon

Since Specialization

Citations

This map shows the geographic impact of Nicolas Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Gordon more than expected).

Fields of papers citing papers by Nicolas Gordon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Gordon. The network helps show where Nicolas Gordon may publish in the future.

Co-authorship network of co-authors of Nicolas Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Gordon. A scholar is included among the top collaborators of Nicolas Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Gordon. Nicolas Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Shafi, Ayesha A., Christopher McNair, Jennifer J. McCann, et al.. (2021). The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications. 12(1). 401–401. 79 indexed citations

Lampert, Erika J., John L. Hays, Elise C. Kohn, et al.. (2019). Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget. 10(30). 2855–2868. 9 indexed citations

Schiewer, Matthew J., Amy C. Mandigo, Nicolas Gordon, et al.. (2019). PARP-1 regulation of DNA repair factor availability.. Journal of Clinical Oncology. 37(7_suppl). 269–269. 1 indexed citations

Lee, Jung Min, John L. Hays, Victoria L. Chiou, et al.. (2017). Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget. 8(45). 79175–79187. 35 indexed citations

Brooks, Nigel, Neil Pegg, Jenny Worthington, et al.. (2017). A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation.. Journal of Clinical Oncology. 35(6_suppl). 168–168. 2 indexed citations

Lee, Jung Min, Cody J. Peer, Minshu Yu, et al.. (2016). Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research. 23(6). 1397–1406. 47 indexed citations

Ahn, Lucie, Takuhei Yokoyama, Minshu Yu, et al.. (2016). Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations. Cancer Research. 76(14_Supplement). 264–264. 1 indexed citations

Lee, Jung Min, Nicolas Gordon, Jane B. Trepel, et al.. (2015). Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. Journal of Translational Medicine. 13(1). 239–239. 13 indexed citations

Chiou, Victoria L., Elise C. Kohn, Christina M. Annunziata, et al.. (2015). Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).. Journal of Clinical Oncology. 33(15_suppl). 5514–5514. 3 indexed citations

10.

Chiou, Victoria L., Christina M. Annunziata, Stanley Lipkowitz, et al.. (2015). Abstract CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers. Cancer Research. 75(15_Supplement). CT326–CT326. 1 indexed citations

11.

Lee, Jung Min, John L. Hays, Christina M. Annunziata, et al.. (2014). Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. JNCI Journal of the National Cancer Institute. 106(6). dju089–dju089. 145 indexed citations

12.

Lee, Jung‐Min, Joyce F. Liu, Peter L. Choyke, et al.. (2014). Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).. Journal of Clinical Oncology. 32(15_suppl). 5535–5535. 3 indexed citations

13.

Lee, Jungmin, Christina M. Annunziata, John L. Hays, et al.. (2014). A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients.. Journal of Clinical Oncology. 32(15_suppl). 5553–5553. 4 indexed citations

14.

Chiou, Victoria L., Elise C. Kohn, Christina M. Annunziata, et al.. (2014). Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062). Cancer Research. 74(19_Supplement). CT337–CT337. 1 indexed citations

15.

Burton, F.G., et al.. (1978). Fabrication and testing of vaginal contraceptive devices designed for release of prespecified dose levels of steroids. Contraception. 17(3). 221–230. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact